AC Immune (ACIU) Operating Leases (2017 - 2026)
AC Immune (ACIU) posted quarterly Operating Leases of $4.4 billion for Q1 2026, up 96334.89% year-over-year from N/an in Q1 2025, and down 3.75% quarter-over-quarter from $4.6 billion in Q4 2025.
AC Immune (ACIU) Operating Leases (2017 - 2026) Analysis & Trends
AC Immune (ACIU) has reported Operating Leases for 9 consecutive years, with $4.4 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Leases rose 96334.89% year-over-year to $4.4 billion; the TTM figure through Mar 2026 stood at $4.4 billion (up 96334.89% YoY), while the FY2025 annual figure was $4.4 billion, up 88465.92% from the prior year.
- Operating Leases declined to $4.4 billion in Q1 2026 per ACIU's latest filing, from $4.6 billion in the prior quarter.
- Across five years, Operating Leases topped out at $4.6 billion in Q4 2025 and bottomed at $2.0 million in Q3 2022.
- Historically, Operating Leases has averaged $987.5 million across 5 years, with a median of $4.5 million in 2025.
- Annual changes were most pronounced in 2022 — Operating Leases plunged 99.91% — and 2023, when it jumped 136079.34%.
- AC Immune's Operating Leases stood at $2.3 million in 2022, then soared by 136079.34% to $3.2 billion in 2023, then tumbled by 99.84% to $5.0 million in 2024, then soared by 91773.3% to $4.6 billion in 2025, then declined by 3.75% to $4.4 billion in 2026.
- Business Quant data shows ACIU's Operating Leases at $4.4 billion in Q1 2026, $4.6 billion in Q4 2025, and $4.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | AC Immune | 253.89 Mn | 253.89 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.13 Mn |
| Mar 31, 2026 | 4.44 Bn |
| Dec 31, 2025 | 4.62 Bn |
| Sep 30, 2025 | 4.52 Mn |
| Jun 30, 2025 | 4.69 Mn |
| Mar 31, 2025 | 4.61 Mn |
| Dec 31, 2024 | 5.02 Mn |
| Sep 30, 2024 | 2.76 Mn |
| Jun 30, 2024 | 2.81 Mn |
| Mar 31, 2024 | 3.04 Mn |
| Dec 31, 2023 | 3.18 Bn |
| Sep 30, 2023 | 2.08 Mn |
| Jun 30, 2023 | 2.20 Mn |
| Mar 31, 2023 | 2.29 Mn |
| Dec 31, 2022 | 2.34 Mn |
| Sep 30, 2022 | 1.97 Mn |
| Jun 30, 2022 | 2.13 Bn |
| Mar 31, 2022 | 2.38 Bn |
| Dec 31, 2021 | 2.54 Bn |
| Sep 30, 2021 | 2.17 Bn |